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Pulmonary tuberculosisAbstract Background: Vitamin D insufficiency/deficiency is associated with impaired immune
function and increased risk of active pulmonary tuberculosis (TB).
Objectives: To evaluate the role of vitamin D as supplementary treatment with the first line anti-
tuberculous drugs (rifampicin, izoniazide, ethambutol and pyrazinamide) in treatment course of
patients with active pulmonary tuberculosis.
Methods: We conducted a case-control study in El Maamora chest hospital, Alexandria gover-
norate, Egypt, including 60 adult patients with active pulmonary TB of 30 patients each. Patients in
group I (cases) received vitamin D (200,000 IU) intramuscular injection once besides anti-
tuberculous drugs, while patients in group II (controls) were randomly selected from the hospital
registry who received the first line anti-tuberculous treatment only. The primary outcome was eval-
uation of conversion time of sputum smear. The secondary outcome was clinical improvement as
assessed by TB score.
Measurements and main results: Mean ± SD age of all patients was 41.55 ± 14.91 years. The
study included 44 (73.3%) males and 16 (26.7%) females. Vitamin D deficiency/insufficiency was
detected in 54 (90%) patients. Comparing the two groups, there was a rapid decline in sputum conver-
sion time and severity classes of TB score in group I compared to group II (p< 0.001 and p= 0.02,
respectively).No complications secondary to supplementary vitaminDweremet all through the study.
Conclusion: Vitamin D accelerates the improvement observed in vitamin D supplemented TB ther-
apy. Vitamin D is safe when added to anti-tuberculous drugs. Vitamin D deficiency/insufficiency is
common among TB patients. Further studies are required to validate this observation and define a
cut off of vitamin D level to prevent immunological alterations.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).a 21131,
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Tuberculosis (TB) is a chronic specific bacterial infection
caused by bacteria of the Mycobacterium tuberculosis [1].
Human monocytes have receptors for 1,25 dihydroxyvitamin
D that activates anti mycobacterial responses in human mono-
cytes and macrophages by enhancing phagocytosis and granu-
loma formation [2].
Vitamin D is synthesized in the skin during exposure to
ultra violet B (UV-B) radiation and is also present in foods.
Vitamin D is readily metabolized in the liver, to form 25
hydroxy-vitamin D [25(OH)D], the accepted measure of vita-
min D status [3,4]. Calcitriol, the active metabolite of vitamin
D, induces anti mycobacterial activity in vitro [2]. This
metabolite modulates the host response to Mycobacterial
infection by induction of reactive nitrogen and oxygen inter-
mediate, [5,6] suppression of matrix metalloproteinase
enzymes implicated in the pathogenesis of pulmonary cavita-
tion [7] and induction of anti microbial peptide catheliciden
[8,9] which induces autophagy [10].
The human vitamin D receptors (VDRs) are polymorphic.
Carriage of the t allele of taq I VDR polymorphism is associ-
ated with an increase in calcitriol-induced phagocytosis of M.
tuberculosis in vitro [11] and more rapid sputum conversion in
patients with pulmonary tuberculosis [12]. While, carriage of f
allele of the fok I VDR polymorphism is associated with a
reduction in transcriptional activity, [13] reduction of
calcitriol-induced phagocytosis, and slower sputum smear or
culture conversion in pulmonary tuberculosis [11].
Lower vitamin D level was reported to be associated with a
higher risk of developing active pulmonary tuberculosis [14].
The role of vitamin D in modifying the treatment course of
pulmonary tuberculosis is still a matter of debate [15,16]. We
aimed this work to evaluate the role of vitamin D as supple-
mentary treatment when added to the first line anti-
tuberculous drugs, (rifampicin, izoniazide, ethambutol, and
pyrazinamide) in the treatment course of patients with active
pulmonary tuberculosis.
Methods
Study site and time
El-Maamoura chest hospital in Alexandria governorate,
Egypt, from January to August 2015.
Study design
We conducted a randomized, case control clinical trial, includ-
ing adult (P18 years old) patients who had active pulmonary
TB diagnosed by sputum examination (smear microscopy or
mycobacterial culture) or byWorldHealthOrganization clinical
criteria [17]. Exclusion criteria were corticosteroids or immuno-
suppressive treatment, human immunodeficiency virus (HIV),
multi-drug resistant TB (MDR-TB), Liver cirrhosis, renal fail-
ure, vitamin D supplementation, malignancies, hypercalcemia.
Patients
This study enrolled sixty patients with active pulmonary tuber-
culosis divided into two groups of thirty patients each. Group I(cases) included patients who received both the first line anti
tuberculous treatment besides supplementary vitamin D
[200,000 IU of vitamin D (25(OH)vitamin D) intramuscular
injection once, (Devarol-S-ampoule, Memphis for pharmaceu-
ticals & chemicals industries, El-Amirya, Cairo, Egypt). Group
II (controls) included patients who were randomly selected
from the hospital registry who received the first line anti tuber-
culous treatment only.
Follow-up
Patients were followed up weekly by microscopic examination
of sputum for acid fast bacilli of pulmonary tuberculosis,
[18,19] and calculation of TB score [20].
Adverse effects
We questioned the patients for the following adverse effects
related to hypercalcemia e.g. nausea, vomiting, excessive thirst,
anorexia, symptoms of kidney stones, and confusion.
Measurements
Body mass index (BMI) was assessed using the following for-
mula: BMI = weight/(height)2. Height was measured by a
meter scale; weight was measured in kilograms, using the same
weight scale at each patient visit. Mid–upper arm circumfer-
ence was measured at the midpoint between the acromion
and olecranon over the biceps of the non dominant arm, using
a non stretchable measuring tape. Severity of TB disease was
assessed by the TB score [20]. TB score has been validated in
another cohort and has been grouped in severity classes as fol-
lows: I (0–5 points), II (6 or 7 points), or III (8 points or more).
Serum level of 25-hydroxyvitamin D [21] was measured at
time of diagnosis and after 2 months of anti-tuberculous ther-
apy with chemiluminescence immunoassay technology using
ADVIA Centaur immunoassay system (Siemens Healthcare
Diagnostics, 1717 Deerfield Road, Deerfield, IL 60015-0778,
USA). Serum vitamin D was defined as deficient (<20 ng/
ml), insufficient (20–30 ng/ml), sufficient (30–100 ng/ml), or
toxic (>100 ng/ml).
Serum levels of Calcium as well as albumin, both were mea-
sured at time of inclusion and at the end of 2nd month. Serum
albumin was measured in order to correct serum calcium using
the following equation: Corrected calcium (mg/dL) = serum
calcium + 0.8 (4  serum albumin (g/dL)) [22] Hypocalcemia,
normo-calcemia or hypercalcemia were defined when corrected
serum calcium levels were below 8.5 mg/dl, 8.5–10.10 mg/dl or
exceeding 10.10 mg/dl, respectively [22].
Outcome
The primary outcome was evaluation of conversion time of
sputum smear. The secondary outcome was clinical improve-
ment as assessed by TB score [20]. The TB score is a newly
developed tool aimed at assessment of change in the clinical
state in patients with TB. It is based on points assigned to signs
and symptoms, including cough, hemoptysis, dyspnea, chest
pain, night sweating, anemia, tachycardia, lung auscultation
finding, fever, low body mass index, and low mid–upper arm
Vitamin D in treatment course of pulmonary tuberculosis 631circumference, giving patients a TB score from 0 to 13. Change
in TB score has been shown to detect clinical change as well; a
high TB score correlates well with mortality and low TB scores
correlate with favorable outcomes, cure, and completed treat-
ment [20].
Statistical analysis
Data were fed to the computer and analyzed using IBM SPSS
software package (IBM SPSS Statistics for Windows, Version
20.0., IBM Corp., Armonk, NY) Qualitative data were
described using number and percent. Quantitative data were
described using range (minimum and maximum) mean, stan-
dard deviation and median. Comparison between different
groups regarding categorical variables was tested using Chi-
square test. When more than 20% of the cells have expected
count less than 5, correction for chi-square was conducted
using Fisher’s Exact test or Monte Carlo correction. McNe-
mar–Bowker and Marginal homogeneity test was applied for
ordinal data .The distributions of quantitative variables were
tested for normality using Kolmogorov–Smirnov test, Sha-
piro–Wilk test and D’Agstino test, If it reveals normal data
distribution, parametric tests was applied. If the data were
abnormally distributed, non-parametric tests were used for
normally distributed data, comparison between the two
studied groups were done using independent t-test, also paired
t-test is used to analyze two paired data. For abnormally dis-
tributed data, comparison was done using Mann Whitney test.
To compare between the different periods, Wilcoxon signed
rank test was applied. Correlations between two quantitative
variables were assessed using spearman coefficients regarding
normality of the data. Significance of the obtained results
was judged at the 5% level.Figure 1 Serum vitamin D measurement in patients in group I at
base line and 2 months after initiation of supplemented treatment.Results
Group I included 22 (73.3%) males and 8 (26.7) females. Sex-
matched controls were selected from the hospital registry
where 22 males and 8 females were included in group II. In
group I, mean ± SD age was 41.70 ± 14.87 years. Age-
matched controls were selected as group II from the registry
with a mean ± SD age of 41.40 ± 14.94 years. There was no
statistically significant difference between the two studied
groups regarding age (p= 0.938). Regarding smoking status,
Group I included 11 (36.7%) non-smokers and 19 (63.35%)
smokers. Group II included 8 (26.7%) non-smokers and 22
(73.3%) smokers. There was no statistically significant differ-
ence between the two groups regarding smoking status
(p= 0.405).
In group I, on commencing the anti-TB treatment, Serum
vitamin D deficiency was defined in 29(96.6%) patients, serum
vitamin D insufficiency was detected in a single (3.4%) patient
while there was no cases where vitamin D sufficiency or serum
vitamin D toxicity was found. Mean serum vitamin D level at
the start of treatment was 9.83 ± 5.88 ng/dl. At the end of 2nd
month, serum vitamin D deficiency was detected in 7 (23.3%)
patients, serum vitamin D insufficiency was traced in 17
(56.7%) patients, serum vitamin D sufficiency was found in 6
(20%) patients, while there were no detected patients with
serum vitamin D toxicity. Mean serum vitamin D level at the
end of second month of treatment was 23.76 ± 7.09 ng/dl.Notably, there was a statistically significant difference between
the cases at the start of treatment and the end of 2nd month of
anti-TB treatment regarding levels of serum vitamin D
(p< 0.001) Fig. 1.
At the start of anti-TB treatment, group I included 22
patients (about 73.3%) who were hypocalcemic, 8 patients
(26.7%) who were normo-calcemic, and there were no patients
with hypercalcemia. The mean corrected serum calcium level at
the start of treatment was 8.19 ± 0.71 mg/dl. At the end of
2nd month of anti-TB treatment, detected 4 patients (about
13.3%) who were hypocalcemic, 15 patients (50%) who were
normo-calcemic, 11 patients (36.7%)who were hypercalcemic.
The mean corrected serum calcium level at the 2nd month of
anti-TB treatment was 3.15 ± 0.55 mg/dl. There was a statisti-
cal significant difference in serum calcium level at the start and
after 2-months of initiating anti-TB treatment (p< 0.001)
Fig. 2.
Group I included 17 patients (56.7%) who were sputum
smear negative for acid fast bacilli at 3rd week, 9 patients
(30%) who were sputum smear negative at 4th week and 4
patients (13.3 %) who were sputum smear negative at 5th
week. Mean conversion time ± SD= 3.57 ± 0.73 weeks.
While group II included 3 patients (10%) who were sputum
smear negative for acid fast bacilli at 5th week, 8 patients
(26.7 %)who were sputum smear negative at 6th week, 5
patients (16.7%) who were sputum smear negative at 7th week
and 14 patients (46.7 %) who were sputum smear negative at
8th week. Mean conversion time ± SD= 7.0 ± 1.08 weeks.
There was a statistical significant difference between the two
groups regarding the time of sputum conversion (p< 0.001)
Figs. 3 and 4.
At the start of anti-TB treatment for patients in group I, 14
patients (46.7%) who were severity class (SC II) and 16
patients (53.3%) who were (SC III), Mean TB score was
2.53 ± 0.51. Group II included 13 patients (about 43.3 %)
who were (SC II) and 17 patients (about 56.7 %) who were
(SCIII), Mean TB score was 2.57 ± 0.50. There was no statis-
tical significant difference between the two groups regarding
TB score at the start of treatment with anti tuberculous drugs
(p= 0.795) Fig. 5.
At the time of conversion of sputum smear or end of 2nd
month, group I included 26 (86.7%) patients who were severity
class (SC I) and 4 (13.3%) patients who were (SC II). Mean TB
Figure 2 Corrected serum calcium level in patients in group I at
baseline and 2 months after initiation of supplemented therapy.
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who were severity class (SC I) and 12 (40%) patients who were
(SC II), Mean TB score was1.40 ± 0.50. There was a statistical
significant difference between the two groups regarding TB
score at the time of conversion of sputum smear or end of
2nd month (p 0.020) Fig. 6.
Discussion
Vitamin D insufficiency/deficiency is associated with impaired
immune function and increased risk of active TB. It has
recently been proposed that vitamin D accelerates resolution
of host inflammatory responses and this may contribute to
the improvement observed in vitamin D supplemented TB
therapy [23].
In the present study, the mean age was 41.70 ± 14.87 years
in patients in group I while it was 41.40 ± 14.94 years in the
control group (II).Similarly, in El Maamora chest hospital,
Mohamed et al. [24] studied the clinical presentation, compli-
cation and outcome of patients suffering from multi-drug resis-
tant tuberculosis (MDR-TB) and extensively drug resistant0 0
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Figure 3 Comparison between the two studied(XDR-TB) and found that the mean age was 40.36
± 14.74 years. Similarly, Sayed et al. [25] studied the role of
interferon gamma release assays (IGRAs) in the diagnosis of
pulmonary TB and found the mean of age was 38.75
± 10.45 years.
This may be explained by fact that TB is a disease of young
and middle-aged adults with most cases occurring between the
ages of 20 to 40 years due to increase of exposure to infection
in this active age group and the effect of physical and mental
stress [26].
The present study revealed that the majority of patients
were males (73.3%) in both groups. Similarly, Mohammed
et al. [24] reported males were 70% of patients, Elrefaey
et al. [27] reported that males were 79.3% of cases.
This coincides with the epidemiological picture of tubercu-
losis where males are more exposed to infection in the commu-
nity than females. Male and female rates of infection are nearly
the same from childhood through young adult life. Thereafter,
the rate of infection in males becomes increasingly greater than
in females in the absence of widespread HIV infection. Also in
some instances, women may have poorer access to the diagnos-
tic facilities [26,28].
Of note, the same or near-same age and gender in both
groups is due to the fact that after enrollment of all patients
in group I, Age and sex-matched controls were chosen from
the hospital registry.
In the current study, the percentage of smokers was
(63.35%) in group (I) and (73.3%) in group (II). The role of
active smoking in development of TB is well known as
described by WHO reports from different countries [29].
Similarly, Oztu¨rk et al. [30] who studied the effect of smok-
ing and indoor air pollution on the risk of tuberculosis found
that patients who smoke had a fivefold (p< 0.0001) higher
odds of having active tuberculosis compared with patients
who do not smoke.
Also Mohammed et al. [24] found that 50% of MDR
patients were tobacco smokers and 46.8% of tuberculous
non-MDR patients were smokers.
Tobacco smoking increases risk ofM. tuberculosis infection
by several means namely; alteration of muco-ciliary clearance,4
0 0 0
3
8
5
14
5th week 6th week 7th week 8th week
Cases Control
groups according to sputum conversion time.
Figure 4 Mean sputum conversion time in both studied groups.
Figure 5 Comparison between the two studied groups according
to TB score at day zero.
Figure 6 Comparison between the two studied groups according
to TB score at sputum conversion or at the end of 2nd month of
initiating supplemented treatment.
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pulmonary lymphocytes, reduction of cytotoxic activity of nat-
ural killer cells and alteration of the activity of the pulmonary
dendritic cells [31].
In the current study, there was a statistical significant differ-
ence between serum vitamin D at the start of anti-TB treat-
ment and that at the end of 2nd month after initiation of
anti-Tb treatment (p< 0.001) .This signifies the good response
of patients with active pulmonary TB to vitamin D supplemen-
tation regardless of the vitamin D state in serum before initia-
tion of vitamin D therapy. Of note, no single case experienced
manifestations of hypercalcemia, 2 months after initiation of
vitamin D therapy, although the presence of elevated serum
calcium level was seen in 11 (36.7 %) patients.
In accordance with our finding, Sita-Lumsden et al. [32]
had reported that patients with active TB had lower serum
vitamin D levels than controls from similar ethnic and social
backgrounds; moreover, even with comparable dietary intake
and sun exposure, they did not show the expected seasonal
variation .Also Nnoaham et al. [14] reported earlier that 25-
hydroxyl cholecalciferol levels were low in patients with TB
compared with that of the healthy controls. Also Arnedo-
Pena et al. [33] reported that vitamin D deficiency is associated
with TB incidence.
Compared to our results, Wejse et al. [34] reported that
vitamin D insufficiency was common among patients with
TB in the study area, but severe vitamin D deficiency was rare.
Vitamin D deficiency or insufficiency in our patients is not
fully explained. This may be attributed to low vitamin D
intake and lack of sun exposure as most of our patients are
of low socioeconomic class.
In the present study, we observed that, there was a signifi-
cant decrease in sputum conversion time in group I (cases)
compared to group II (control) (p< 0.001). Sputa of most
patients (56.7%) in group I were converted at the 3rd week
of initiation of anti-TB drugs while in group II, sputa of most
patients (46.7%) were converted at the 8th week after the start
of anti-TB therapy.
Our later finding is supported by many studies in the liter-
ature. Sato et al. [35] reported that in cured patients, serum 25
hydroxy-vitamin D levels showed a significantly negative cor-
relation with duration until sputum conversion. This relation-
ship suggests that a low serum vitamin D level may not only be
a risk factor for the development of active TB but it may also
be related to poor treatment outcomes in active TB patients.
Furthermore, Kota et al. [36] who studied the effect of vitamin
D supplementation in type 2 diabetes patients with pulmonary
tuberculosis, reported that in subjects receiving 60,000 IU
cholecalciferol per week along with anti-TB treatment, dura-
tion of sputum conversion to 100% negative for AFB was
6 weeks compared to 8 weeks in subjects not receiving chole-
calciferol. Also, Nursyam et al. [37] reported that pulmonary
TB patients given 420,000 IU of vitamin D over 6weeks had
significantly higher sputum conversion rates as compared to
placebo (p 0.002).
Compared to our finding, Martineau et al. [38] demon-
strated that administration of four doses of 2.5 mg vitamin
D (100,000 IU, 1 mg = 40,000 IU) did not affect time to spu-
tum culture conversion in the whole study group. However,
improvement of the serum vitamin D level was experienced
both safely and quickly and a faster conversion to negative
sputum for AFB was encountered in patients with tt genotype
634 E.G. Hassanein et al.of the Taq I vitamin D receptor polymorphism suggesting that
this subgroup of patients with TB might derive clinical benefit
from vitamin D supplementation.
Unfortunately and to the best of the authors’ knowledge,
no available data exist regarding the genotypes of vitamin D
receptor polymorphism in Egyptian tuberculous patients.
In the current study, there was a statistical significant differ-
ence between serum calcium at the start of anti-TB treatment
and that measured at the end of 2nd month after initiation
of anti-TB treatment (p< 0.001). Narang et al. [39] reported
similar results. Hypercalcemia was detected in 19 of 30 patients
with smear positive pulmonary tuberculosis taking a daily dose
of 10–95 mg vitamin D.
Compared to our results, Martineau et al. [38] showed that
serum corrected calcium concentration declined in both inter-
vention and control arms after initiation of antimicrobial treat-
ment. Such a decline might have resulted from a reduction in
granulomatous burden in patients responding to treatment,
leading to a decrease in extra-renal 1-alpha hydroxylation
of 25-hydroxy-vitamin D and a fall in serum 1, 25-
dihydroxyvitamin D concentrations.
TB score assessed at the end of treatment also strongly
predicted subsequent mortality. The TB score is a simple and
low-cost tool for clinical monitoring of tuberculosis patients
in low-resource settings and may be used to predict mortality
risk. Low TB score or fall in TB score at treatment completion
may be used as a measure of improvement [40].
In the current study, there was a statistical significant differ-
ence between the two groups regarding TB score at the time of
sputum conversion or at the end of the 2nd month after the
start of anti-tuberculous treatment (p 0.020).
Wejse et al. [34] found that TB score declined for 96% of
the surviving patients from initiation to end of treatment,
and declined with a similar pattern in HIV-infected and
HIV-uninfected patients, as well as in smear negative and
smear positive patients. The risk of dying during treatment
increased with higher TB score at inclusion. For patients with
a TB score of >8 at inclusion, mortality during the 8 months
treatment was 21% (45/218) versus 11% (55/480) for TB score
<8 (p< 0.001).
On contrary, Janols et al. [41] reported that in TB patients
(53.6% of whom were HIV co-infected), the median TB score
declined from week 0 to week 2 (8 (IQR 6–9) vs 4 (IQR 2–6))
and dropped to a low level at week 8, which was still signifi-
cantly higher than that found in blood donors (2 (IQR 1–4)
vs 0 (IQR 0–1), p< 0.0001). Patients who died had a signifi-
cantly higher TB score at week 0, week 2, and week 8 than
survivors. Mortality was associated with a failure to achieve
a decrease greater than 25% in the TB score at 2 weeks.
Baseline CD4+ cell counts (<200 cells/mm3) were associated
with mortality but not with initial TB score results. They con-
cluded that the TB score was increased during the first
2 months of treatment among patients who died. Failure to
achieve a greater than 25% decrease in TB score after 2 weeks
of treatment was associated with increased mortality.
Repeated clinical scoring during the intensive phase of TB
treatment could be useful to identify high-risk patients.
In conclusion, supplementary vitamin D when added to
first line anti-tuberculous drugs was of benefit in treatment
of active pulmonary TB. This results in shorter conversion
time and less severe TB clinical manifestation without any
notable manifestations of hypercalcemia. Therefore, it isrecommended to add vitamin D as supplementary treatment
to first-line anti-tuberculous drugs in the treatment course of
active pulmonary TB.Conflict of interest
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